Prophylaxis for Recurrent Urinary Tract Infection in Severe Benign Prostatic Hyperplasia

Primary BPH Management

Relieving bladder outlet obstruction is the most critical step to prevent recurrent UTIs in patients with severe BPH. 1
Severe BPH creates bladder outlet obstruction that raises post‑void residual urine, providing a reservoir for bacterial growth and recurrent infections. 1
Initiate an alpha‑blocker (e.g., tamsulosin, alfuzosin, doxazosin, terazosin) to reduce prostatic smooth‑muscle tone and improve bladder emptying. 1
Add a 5‑alpha‑reductase inhibitor (finasteride or dutasteride) when prostate volume exceeds 30 cc; combination therapy lowers disease progression risk to < 10 % versus 10‑15 % with monotherapy. 1

Refer for surgery if acute urinary retention occurs despite optimal medical therapy. 1
Refer for surgery if medical management fails after 4–12 weeks of treatment. 1
Do not rely solely on antimicrobial prophylaxis without first addressing the mechanical obstruction caused by BPH. 1
Early surgical referral for patients with complications (recurrent UTIs, retention, bladder stones, or gross hematuria) prevents progressive bladder dysfunction. 1

Increase daily fluid intake to promote bladder washout and reduce bacterial colonisation. 2
Use immunoactive prophylaxis (OM‑89/Uro‑Vaxom) to lower recurrence rates of UTIs across all adult age groups. 2
Methenamine hippurate may be employed in patients without structural urinary abnormalities; its benefit diminishes when post‑void residual volumes are high. 2
D‑mannose or cranberry products can be considered, but current evidence is weak and contradictory. 2

Continuous prophylaxis with trimethoprim‑sulfamethoxazole 160/800 mg daily or three times per week can be used after optimisation of BPH therapy and non‑antimicrobial strategies. 2
Nitrofurantoin 50–100 mg daily is an alternative for patients with estimated glomerular filtration rate > 30 mL/min. 2
For highly compliant patients able to recognise early UTI symptoms, a self‑administered short‑course antibiotic regimen may be employed. 2

Reassess patients 4–12 weeks after initiating BPH therapy using the International Prostate Symptom Score (IPSS), post‑void residual measurement, and uroflowmetry to gauge treatment response. 1
Obtain a urine culture for every suspected UTI episode to confirm infection and guide targeted antimicrobial selection. 2
If UTIs persist despite optimized BPH management and non‑antimicrobial prophylaxis, transition to continuous antimicrobial prophylaxis. 2

Alpha-adrenergic blockers should be the first-line medication for BPH treatment, providing effective symptom relief by inhibiting alpha1-adrenergic-mediated contraction of prostatic smooth muscle, with a 4-6 point improvement in the AUA Symptom Index 3, 4
The choice between alpha-blockers can be based on side effect profiles, with tamsulosin having fewer blood pressure effects compared to others 4

Post-void residual measurement is essential to assess bladder emptying and potential urinary retention 5
Urethrocystoscopy should be performed to evaluate the bladder mucosa and rule out other conditions like bladder cancer, especially with history of hematuria 6

Alpha-blocker therapy for BPH symptoms, such as tamsulosin, alfuzosin, doxazosin, or terazosin, can be used in combination with an antimuscarinic medication or beta-3 agonist for patients with both BPH and storage symptoms 4, 7, 8
Combination therapy has shown significant improvements in symptoms compared to monotherapy in patients with mixed voiding and storage symptoms 8

Regular follow-up is necessary to assess symptom improvement and medication side effects, with repeat PVR measurement to ensure adequate bladder emptying 8, 9
If symptoms persist despite medical therapy, consider urodynamic studies to better characterize the bladder dysfunction 10

Surgical intervention for BPH may be indicated if chronic cystitis is associated with recurrent UTIs, recurrent gross hematuria, or bladder stones 11
Large PVR volumes may indicate significant bladder dysfunction and predict a less favorable response to medical treatment 10
Patients with moderate to severe symptoms who are not bothered by them may be managed with watchful waiting rather than active treatment 5

Avoid antimuscarinic medications in patients with very high PVR, as they can exacerbate urinary retention 8
Prompt urological referral is indicated if symptoms persist despite medical therapy or if complications develop, such as recurrent UTIs, hematuria, or bladder stones 11